Merge eClinical Announces New Mobile App
Study Connect™ App Enables the Mobile Management of Randomization, Inventory Management and Unblinding in Clinical Trials
Study Connect™, a new mobile app from Merge eClinical, allow users of its eClinicalOS (eCOS) to perform a wide array of clinical trial management functions from their iOS-based mobile devices.
Seamlessly integrated with eCOS, Study Connect™enables researchers to:
· Manage randomization of subjects
· Coordinate dispensing and inventory management
· Unblind individual subjects, as circumstances warrant
· Stay connected with real-time customized notifications
· Monitor enrollment and establish milestone alerts
· Share top-level statistics for each study with key stakeholders using the study dashboard
· Expedite approval response times for critical study decisions such as patient study eligibility
· Maintain security with the ability to set customized role-based permissions for individual studies.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
